Triclinic Labs, Inc. announced that it has completed the 5000 square feet, Phase II expansion of its laboratory spaces in order to offer more capacity and new solid-state chemical development services.
LAFAYETTE, Ind., July 19, 2022 /PRNewswire-PRWeb/ -- The approximately 5000 square feet of new laboratory space includes dedicated areas for solid form crystallization screening, chemical synthesis, materials characterization, analytical method development, and amorphous solid dispersion formulation development. In addition to six hoods, one walk in hood, and an environmentally controlled space for mass spectrometry services, Triclinic invested more than two million dollars in new equipment and capabilities.
"We are excited to open the new space which will not only provide significantly more capacity for polymorph, pharmaceutical salt, and cocrystal screening projects, but also delivers the needed space for new services like ICP-MS, LC-MS, spray drying, hot melt extrusion, and amorphous formulation development," said Dr. Aeri Park, Triclinic's Chief Operating Officer. "We have added space as well as subject matter experts over the last six months to meet client demands and it's great to finally put both capabilities together," she continued.
Media Contact
Shawn Comella, Triclinic Labs, Inc, 1 7655886200 Ext: 302, [email protected]
Aeri Park, Ph.D., Triclinic Labs, Inc, 7655886200 313, [email protected]
SOURCE Triclinic Labs, Inc
Share this article